Target Price | $70.27 |
Price | $59.92 |
Potential |
17.28%
register free of charge
|
Number of Estimates | 11 |
11 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2025 .
The average Rhythm Pharmaceuticals, Inc. target price is $70.27.
This is
17.28%
register free of charge
$84.00
40.19%
register free of charge
$58.00
3.20%
register free of charge
|
|
A rating was issued by 11 analysts: 10 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2025 of
17.28%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 77.43 | 124.46 |
227.54% | 60.73% | |
EBITDA Margin | -235.83% | -213.01% |
68.64% | 9.67% | |
Net Margin | -253.92% | -210.14% |
71.93% | 17.24% |
11 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2024 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2024. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.20 | -4.26 |
8.05% | 33.13% | |
P/E | negative | |
EV/Sales | 29.24 |
3 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Rhythm Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.